Cargando…
New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400777/ https://www.ncbi.nlm.nih.gov/pubmed/36046357 http://dx.doi.org/10.37349/etat.2022.00069 |